Life Sciences and Pharma IP Litigation 2025

SWITZERLAND CONTENTS

4. Patent Term Extensions for Pharmaceutical Products p.330 4.1 Supplementary Protection Certificates p.330 4.2 Paediatric Extensions p.331 4.3 Paediatric-Use Marketing Authorisations p.331 4.4 Orphan Medicines Extensions p.331 5. Relief Available for Patent Infringement p.331 5.1 Preliminary Injunctive Relief p.331 5.2 Final Injunctive Relief p.332 5.3 Discretion to Award Injunctive Relief (Final or Preliminary) p.332 5.4 Damages p.333 5.5 Legal Costs p.333 5.6 Relevance of Claimant/Plaintiff Conduct to Relief p.334 6. Other IP Rights p.334 6.1 Trade Marks p.334 6.2 Copyright p.334 6.3 Trade Secrets p.334 7. Appeal p.334 7.1 Timeframe to Appeal Decision p.334 7.2 Appeal Court(s) Arbiter p.335 7.3 Special Provisions p.335 8. Other Relevant Forums/Procedures p.335 8.1 The UPC or Other Forums p.335 9. Alternative Dispute Resolution p.335 9.1 ADR Options p.335 10. Settlement/Antitrust p.336 10.1 Considerations and Scrutiny p.336 11. Collective Redress p.336 11.1 Group Claims p.336

319 CHAMBERS.COM

Powered by